A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Fiche publication

Date publication

septembre 2018

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAUCHESNE Patrick , Pr GHIRINGHELLI François

Tous les auteurs :
Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30266892

Résumé

We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients with recurrent glioblastoma who had progressed after first-line treatment with radiotherapy, temozolomide, and BEV.